Results

Total Results: 1,424 records

Showing results for "topical treatment".

1381. Dietary Total Fat Intake and Dietary Polyunsaturated Fatty Acid Intake and Child Growth and Development Outcomes: A Systematic Review (pdf file)
      effectivehealthcare.ahrq.gov/sites/default/files/wysiwyg/pdf/child-growth-development-outcomes-protocol.pdf
      August 19, 2024 - consumer education materials, such as the nutrition facts panels on food packaging, in medical nutrition therapy … relevant, allocation of subjects to exposure; report similar baseline characteristics in different treatment

1382. Public-Reporting-Cost-Measures Technical-Brief (pdf file)
      effectivehealthcare.ahrq.gov/sites/default/files/pdf/public-reporting-cost-measures_technical-brief.pdf
      March 01, 2015 - Public reporting may also improve how health care resources are consumed by promoting the use of treatments … transparency is normally targeted before consumers seek care so they can be empowered to make informed treatment … , 2011 Agency for Healthcare Research and Quality Original Research X X Barlas, 2010 Pharmacy and Therapeutics … Pharmacy and Therapeutics 2010;35(7):369-372. Catalyst for payment reform. … Within these care settings, the vendors report on costs for medical treatments, procedures, imaging

1383. CER 216 Disposition of Comments Report: Telehealth for Acute and Chronic Care Consultations (pdf file)
      effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-216-telehealth-disposition-comments.pdf
      April 24, 2019 - also be noted that the author’s methodology excluded a signif icant body of w ork on diagnostic and treatment

1384. Research to Improve the Delivery of Clinical Preventive Services to People with Disabilities (pdf file)
      effectivehealthcare.ahrq.gov/sites/default/files/wysiwyg/stakeholder-report_0824.pdf
      August 01, 2024 - Blood pressure screening, control, and treatment for patients with developmental disabilities in general

1385. The Effect of Dietary Digestible Carbohydrate Intake on Risk of Cardiovascular Disease (pdf file)
      effectivehealthcare.ahrq.gov/sites/default/files/related_files/risk-cardiovascular-disease.pdf
      January 01, 2023 - diagnosed with the endpoint outcomes of interest) • Participants who intend to reduce weight or receive treatments

1386. Disposition of Comments for Technical Brief 20 Core Functionality in Pediatric Electronic Health Records (pdf file)
      effectivehealthcare.ahrq.gov/sites/default/files/related_files/pediatric-ehr_disposition-comments.pdf
      May 01, 2015 - Does "improving children's health" include prevention or other therapies that might just maintain health … federal, State, and local reporting requirements, as well as changing recommendations on care and treatment … milestones are not reached and improving early referral to specialty health care services such as Physical Therapy … are not reached and improving early referral to specialty health care services, such as Physical Therapy … disease and cystic fibrosis clearly demonstrate the value of moving data and assuring that appropriate therapy

1387. Evidence-based Practice Center Systematic Review Protocol (pdf file)
      effectivehealthcare.ahrq.gov/sites/default/files/pdf/cerebral-palsy-feeding_research-protocol.pdf
      June 12, 2012 - intake), and concurrent medications that potentially have gastrointestinal side effects may influence treatment … www.effectivehealthcare.ahrq.gov/ Source: www.effectivehealthcare.ahrq.gov Published Online: June 12, 2012 treatment … Practice parameter: pharmacologic treatment of spasticity in children and adolescents with cerebral … "[mesh] OR "occupational therapy"[tiab] OR "Behavior Therapy"[mesh] OR "behavior therapy"[mesh] OR … " OR KW="Behavioral Therapy" OR KW="Behavior Therapy" OR KW="Behavior Modification" OR KW="Behavior"

1388. Outcome Measure Framework Design Document (pdf file)
      effectivehealthcare.ahrq.gov/sites/default/files/wysiwyg/registry-of-patient-registries_research-2014.pdf
      January 01, 2014 - purposes for patient registries include evaluating the safety, effectiveness, or quality of medical treatments … Examples of outcome measures Title Definition Type Response to rituximab treatment Reduction of … Patient French AutoImmunity and Rituximab (AIR) Registry Response to rituximab treatment, as measured

1389. Disposition of Comments for PCA3 Testing for the Diagnosis and Management of Prostate Cancer (pdf file)
      effectivehealthcare.ahrq.gov/sites/default/files/related_files/prostate-cancer-test_disposition-comments.pdf
      April 01, 2013 - KI # 9 Introduction p. 22, line 52 There are well established treatments for all risk strata of prostate … newer studies are being conducted of focal treatment with these modalities. … This point is noted and focal treatment has been omitted. … not really managed using PCA3 and one cannot tell clinical outcomes can be improved by selecting treatments … and aggressiveness of treatment using the assay.

1390. Hepatic-Fibrosis White-Paper (pdf file)
      effectivehealthcare.ahrq.gov/sites/default/files/pdf/hepatic-fibrosis_white-paper.pdf
      April 01, 2014 - Use of AST platelet ratio index (APRI Score) as an alternative to liver biopsy for treatment indication … Assessment of liver fibrosis before and after antiviral therapy by different serum marker panels … A non- invasive fibrosis score predicts treatment outcome in chronic hepatitis C infection. … Use of AST platelet ratio index (APRI Score) as an alternative to liver biopsy for treatment indication … A non- invasive fibrosis score predicts treatment outcome in chronic hepatitis C infection.

1391. Evidence-based Practice Center Systematic Review Protocol (pdf file)
      effectivehealthcare.ahrq.gov/sites/default/files/pdf/disabilities-quality-improvement-outcomes_research-protocol.pdf
      August 03, 2011 - which are manifestations of disease processes, and disabilities that are iatrogenically acquired from treatments … We will search MEDLINE, EPOC (for organizational quality improvement efforts), PEDRO (physical therapy … Physical Therapy 2006, 86(5):726-734 VI.

1392. Transparency of Reporting Requirements: Omega-3 Fatty Acids and Cardiovascular Disease (pdf file)
      effectivehealthcare.ahrq.gov/sites/default/files/pdf/transparency-omega-3_research-protocol.pdf
      September 02, 2016 - Reporting Bias in Clinical Trials Investigating the Efficacy of Second-Generation Antidepressants in the Treatment

1393. Cancer-Ovarian-Contraceptives Executive (pdf file)
      effectivehealthcare.ahrq.gov/sites/default/files/related_files/cancer-ovarian-contraceptives_executive.pdf
      June 01, 2013 - highest incidence (60 years and older).2 While advances in surgery, chemotherapy, and radiation therapy … research agenda and clinical recommendations, as evidenced by the experience with hormone replacement therapy … in preventing unintended pregnancies; the potential effectiveness of OCs as primary or adjunctive treatments … with the target population, version or characteristics of the intervention used in comparison with therapies … be reassuring to women considering OCs for contraception and to women who are prescribed OCs for treatment

1394. Improving Health Care and Palliative Care for Advanced and Serious Illness Disposition of Comments Report (pdf file)
      effectivehealthcare.ahrq.gov/sites/default/files/related_files/quality-gap-palliative-hospice_disposition-comments.pdf
      October 01, 2012 - clear how these 8 studies differ from the hundreds of studies of pain, dyspnea, and other symptom treatment

1395. Omega−3 Fatty Acids and Cardiovascular Disease: An Updated Systematic Review (pdf file)
      effectivehealthcare.ahrq.gov/sites/default/files/related_files/fatty-acids-cardiovascular-disease_executive.pdf
      August 01, 2016 - There have been secular trends in the prevention and treatment of CVD over the past several decades, … trends are the lower rates of cardiac and cerebrovascular disease, concomitant with higher rates of treatment … These treatment trends may have contributed to the lower population-level CV benefit of higher n-3 FA … nutrients or supplements, and drugs (e.g., statins, aspirin, diabetes drugs, hormone replacement therapy … nutrients or supplements, and drugs (e.g., statins, aspirin, diabetes drugs, hormone replacement therapy

1396. Screening for and Management of Chronic Kidney Disease Stages 1-3 | Effective Health Care (EHC) Program
      effectivehealthcare.ahrq.gov/products/kidney-disease-medicine/research-protocol

1397. Disposition of Comments for Evidence Report 224 Omega-3 Fatty Acids (pdf file)
      effectivehealthcare.ahrq.gov/sites/default/files/related_files/omega-3-maternity_disposition-comments.pdf
      October 12, 2016 - 2016 6 Commentator & Affiliation Section Comment Response Peer Reviewer #2 General comments Treatment

1398. Prostate-Cancer-Risk-Assessment-Genes Executive (pdf file)
      effectivehealthcare.ahrq.gov/sites/default/files/related_files/prostate-cancer-risk-assessment-genes_executive.pdf
      July 01, 2012 - stratification will depend to a large extent on clearer evidence that surveillance, diagnostic, and treatment

1399. Public-Reporting-Cost-Measures Research-Protocol (pdf file)
      effectivehealthcare.ahrq.gov/sites/default/files/pdf/public-reporting-cost-measures_research-protocol.pdf
      January 13, 2014 - healthpolicybrief_65.pdf Joy M, Little E, Maruthur N, Purnell T, Bridges J (2013) Patient preferences for the treatment

1400. DRN: Report 1 (pdf file)
      effectivehealthcare.ahrq.gov/sites/default/files/pdf/distributed-network-safety_research.pdf
      July 01, 2009 - used across a range of practitioners, settings, and demographic groups and the associated therapeutic … ; assessing long-term outcomes of treatments; and collecting new information about therapies at the … very large individual databases and registries may not have a sufficient number of cases to detect treatment … kidney disease in patients whose blood pressure remains uncontrolled after initiation of 1st line therapy … Identify and characterize use of a newly-approved therapy, including users, dispensings, and exposure